Telix Pharmaceuticals (TLX) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 148.5% versus a loss of 6.1%. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.84 billion), about 1.1 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +43.7%). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLX | XERS |
|---|---|---|
| Share price | $8.37 | $16.97 |
| Market cap | $2.84B | $3.10B |
| 1-day change | -3.90% | +2.11% |
| YTD return | +11.75% | +116.18% |
| 1-year return | -6.06% | +148.46% |
| 5-year return | — | +682.03% |
| P/E ratio (TTM) | 83.70 | — |
| Forward P/E | — | 63.64 |
| EPS (TTM) | $0.10 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $803.79M | $291.85M |
| Revenue growth (YoY) | +55.61% | +43.72% |
| Net income (latest FY) | $-7.13M | $554.00K |
| Gross margin | 53.05% | 85.41% |
| Operating margin | 3.70% | 8.53% |
| Net margin | -0.89% | 0.19% |
| 52-week high | $13.11 | $17.28 |
| 52-week low | $6.28 | $5.25 |
| Distance from 52-week high | -36.16% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +134.89% | +1.89% |
| Average volume | 356.74K | 2.86M |
| Shares outstanding | 339.78M | 182.70M |
| Employees | 1,120 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed TLX by 154.5 percentage points over the past year.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +43.72%).
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
TLX vs XERS FAQ
Which is bigger, Telix Pharmaceuticals or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.84B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, TLX or XERS?
XERS returned +148.46% over the past 12 months, compared with -6.06% for TLX (price return, excluding dividends). Past performance does not predict future results.
Are Telix Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.